It sounds like you want to level an accusation around trial data, but are unable to articulate it accurately, or follow through on committing to it in writing in a manner that could see it addressed.
Is there any danger of letting the trial come to a conclusion before you put Veyonda in the bin based on, shall we repeat again, PHASE 1 interim data.
Ann: Veyonda and Radiotherapy Delivers Clinical Benefits, page-22
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $555 | 5.296K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 95000 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 151971 | 2 |
View Market Depth
| Last trade - 15.18pm 22/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
